FIGURE 1.

AMI treatment alters circulating murine metabolic factors and body weight. A, alterations in body weight between AMI-treated and vehicle-treated male HD mice (vehicle-treated, black line, AMI-treated, gray line). B, alterations in body weight between AMI-treated and vehicle-treated female HD mice (vehicle-treated, black line; AMI-treated, gray line). C, alterations in body weight between AMI-treated and vehicle-treated male WT mice (vehicle-treated, black line; AMI-treated, gray line). D, AMI-mediated effects on fasting glucose in HD mice. E, AMI-mediated effects on fasting insulin in HD mice. F, AMI-mediated effects on the plasma triglyceride levels in HD mice. G, AMI-mediated effects on the plasma total ketone bodies levels in HD mice. Effects of AMI treatment on levels of leptin (H), peptide YY (PYY, I), pancreatic polypeptide (PP, J), and gastrointestinal inhibitory peptide (GIP, K) in HD mice. L, AMI-mediated effects on fasting glucose in WT mice. M, AMI-mediated effects on fasting insulin in WT mice. N, AMI-mediated effects on the plasma triglyceride levels in WT mice. O, AMI-mediated effects on the plasma total ketone bodies levels in WT mice. Effects of AMI treatment on levels of leptin (P), peptide YY (PYY, Q), pancreatic polypeptide (PP, R), and gastrointestinal inhibitory peptide (GIP, S) in WT mice. Data are means ± S.E. *, p ≤ 0.05, n = 12/group.